DOCSLIB.ORG

Sudden Cardiac Death: Use of Genetics in the Diagnosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sudden Cardiac Death: Use of Genetics in the Diagnosis Sudden Cardiac Death: Use of Genetics in the diagnosis Ramon Brugada MD PhD [email protected] “Genetic testing is expensive; the system can not afford it” However, the real question is can we, physicians, afford not doing it? CORONARY ARTERY DISEASE CAUSES 80% OF SUDDEN CARDIAC DEATHS What do young people die from? From the patient to the research laboratory BRUGADA SYNDROME SHORT QT SCN5A SYNDROME KCNH2 HYPERTROPHIC LONG QT CARDIOMYOPATHY SYNDROME MYOSIN HEAVY CHAIN KCNQ1 DILATED CARDIOMYOPATHY MARFAN SYNDROME LAMIN A/C FIBRILLIN-1 Genetics of Sudden Cardiac Death Hypertrophic Cardiomyopathy Assymetric hypertrophy of the left ventricle. Most common cause of sudden cardiac death in the athlete. Steve R. Ommen, and Bernard J. Gersh Eur Heart J 2009 Dilated Cardiomyopathy Gene Symbol Gene Symbol Cardiac α-actin ACTC Telethonin (T-cap) TCAP β-Myosin heavy chain MYH α-Sarcoglycan SGCA Cardiac troponin T TNNT2 β-Sarcoglycan SGCB α-Tropomyosin TPM1 δ-Sarcoglycan SGCD Titin TTN Dystrophin DMD Arrhythmogenic Right Ventricular Dysplasia Right ventricular dilatation Fibro adipose myocardial substitution Sudden death often the first symptom Sudden Cardiac Death: Electrical Short QT syndrome Brugada syndrome CPVT Long QT syndrome Long QT syndrome: Diagnosis Short QT syndrome: Diagnosis Gollob MH et al. J Am Coll Cardiol 2011 Catecholaminergic polymorphic ventricular tachycardia Brugada Syndrome Diagnosis Genetic diseases associated with sudden cardiac death CARDIOMYOPATHIES CHANNELOPATHIES Sudden Death: Monogenic diseases Diseases associated with SCD Channelopathies Cardiomyopathies 60% 30% 50% 50% 80% 60% 60% From the research laboratory to the patient BRUGADA SYNDROME SHORT QT SCN5A SYNDROME KCNH2 HYPERTROPHIC CARDIOMYOPATHY LONG QT MYOSIN HEAVY CHAIN SYNDROME KCNQ1 DILATED CARDIOMYOPATHY MARFAN SYNDROME LAMIN A/C FIBRILLIN-1 Give an answer to the families Research Translation Bringing research to the bedside 2007 -Consensus report on risk stratification in BrS 2008 -Consensus report on ion channelopathies 2009 -Compendium of scn5a gene mutations 2010 -Canadian recommendations on genetic testing 2011 -American and European recommendations Clinical Guidelines Heart Rhythm 2011 Added value of genetics Recommendations on genetic testing Disease Genetic Panel Patients Family Long QT Syndrome (LQTS) KCNQ1, KCNH2, SCN5A It is recommended It is recommended Catecholaminergic Polymorphic It is recommended RYR2, CASQ2 It is recommended Ventricular Tachycardia (CPVT) Brugada Syndrome (BrS) SCN5A Can be useful It is recommended Short QT Syndrome (SQTS) KCNH2, KCNQ1, KCNJ2 May be considered It is recommended Hypertrophic Cardiomyopathy MYH7, MYBPC3,TNNT2, TNNI3, It is recommended It is recommended (HCM) TPM1 Arrythmogenic right ventricular DSC2, DSG2, DSP, PKP2, It is recommended Can be useful cardiomyopathy (ARVC) TMEM43, JUP Dilated cardiomyopathy (DCM) LMNA, SCN5A It is recommended It is recommended It is recommended Left Ventricular MYH7, ACTC1, TNNT2, MYBPC3, Can be useful LBD3 noncompactation (LVnC) Restrictive cardiomyopathy MYH7, ACTC1, TNNT2, TNNI3, May be considered It is recommended (RCM) It is recommended Clinically guided It is recommended Sudden Death Survival Forensic Analysis in SCD. RYR2, KCNQ1, KCNH2, SCN5A It is recommended It is recommended Requirements for Clinical Genetic Testing - State of the art laboratory - State of the Art technology - State of the Art technical procedures - State of the Art bioinformatics analyses - High quality diagnostic tools - Fast - Efficient - Reliable results State of the Art technology Variant name Gene Consequence cDNA 4_114213631_C/T ANK2 SYNONYMOUS_CODING 2390 CACNA 12_2558186_G/A 1C SYNONYMOUS_CODING 612 6_7577260_C/T DSP SYNONYMOUS_CODING 3203 15_48797307_A/G FBN1 SYNONYMOUS_CODING 2203 NON_SYNONYMOUS_CODIN 1_156106775_C/T LMNA G 1656 14_23874507_G/T MYH6 SYNONYMOUS_CODING 481 14_23899060_G/A MYH7 SYNONYMOUS_CODING 1140 NON_SYNONYMOUS_CODIN 3_38645420_T/C SCN5A G 1867 15_63351873_T/C TPM1 SYNONYMOUS_CODING 691 1_116311367_CA/- CASQ2 5PRIME_UTR 35-36 1_236926026_-/G ACTN2 3PRIME_UTR 2957-2958 1_237586384_T/C RYR2 SPLICE_SITE N/A 1_237996581_G/A RYR2 3PRIME_UTR 15856 CACNB 10_18439810_A/T 2 ESSENTIAL_SPLICE_SITE N/A 10_75879750_G/A VCL 3PRIME_UTR 5322 10_75879777_-/C VCL 3PRIME_UTR 5348-5349 10_88495504_C/G LDB3 3PRIME_UTR 4993 15_48779402_C/T FBN1 SPLICE_SITE N/A State of the Art bioinformatics Causal or Normal variant? State of the Art Research and Development The ion channel: the generator of the electrical activity GENE EXPRESSION TRAFFIC TO MEMBRANE GENETICS POSTRANSLATIONAL MODIFICATIONS FUNCTIONAL ACTIVITY Requirements for Clinical Genetic Testing - State of the art laboratory - State of the Art technology - State of the Art technical procedures - State of the Art bioinformatics analyses - State of the Art Research and Development - High quality diagnostic tools - Fast - Efficient - Reliable results - Specialized support - Clinical support pre-genetic testing - Own pipeline pathogenicity algorithms - Support for genetic data interpretation - Support for clinical decision making Interfamily variability C1764G N588K C1764A N588K Intrafamily variation Confirm a Genetic Diagnosis MISSENSE MUTATION MYOSIN HEAVY CHAIN Reach a Diagnosis 54 years DELETION SYNCOPE DESMOPLAKINE Diagnosis based on the presence of a mutation Guide therapy and prevention Evaluation of borderline cases Complement clinical tests Identify non carriers Decisions on offspring ? Diagnosis in Unexplained sudden cardiac death One third of the unexplained deaths in the young are caused by a genetic cardiac disease Clinical cases Clinical cases 17 yo. SCD while exercising Clinical cases Clinical cases Septum 16 mm Normal ECO Clinical cases Septum 9 mm Septum 16 mm Septum 10 mm Septum 8 mm Clinical cases Mutation MYH7 No Mutation MYH7 Septum 9 mm Septum 16 mm Septum 10 mm Septum 8 mm Clinical cases 8 yo SCD No ECG Clinical cases 40 years old SCD Clinical cases Clinical cases 45 years old Collapse in college QTc 460 Procainamide + Clinical cases 44 years old asymptomatic QTc 480 Clinical cases 31 years old asymptomatic QTc 420 Sudden cardiac death in Canary Islands - Family with more than 2000 members - 32 patients died suddenly at young age Sudden cardiac death in Canary Islands Basal ECG Isolated premature ventricular beats Exercise progression Bidirectional ventricular arrhythmia SCD in the Canary islands Cardiac events in the family p.G357S Clinical cases TTN_p.Q18907X Epilepsy 23 yo Sudden cardiac death Hx of epilepsy for 20 years Sister with epilepsy Epilepsy 23 yo Sudden cardiac death Hx of epilepsy for 20 years Sister with epilepsy Palpitations previous to epilepsy Associated with sudden loud noise Epilepsy KCNH2_p.G604S Importance of segregation studies ? ? LQS and Epilepsy epilepsy SUDEP LQTS Importance of segregation studies ? ? KCNE1 LQS and Epilepsy HTR2A epilepsy CDKL5 KCNQ1 CDKL5 SUDEP LQTS Deletion Exon 2 KCNQ1 KCNQ1 p.R98W (c.292C>T) KCNE1 KCNE1 p.PI206V (c.616A>G) HTR2A p.R914K (c.2714G>A) CDKL5 Importance of segregation studies ? ? KCNE1 LQS and Epilepsy HTR2A epilepsy CDKL5 KCNQ1 CDKL5 SUDEP LQTS Deletion Exon 2 KCNQ1 KCNQ1 The deletion of exon 2 of KCNQ1 p.R98W (c.292C>T) KCNE1 KCNE1 gene could explain the LQTS and the p.PI206V (c.616A>G) HTR2A variant in CDKL5 gene could explain p.R914K (c.2714G>A) CDKL5 the epilepsy in this family Gencardio-SUDEP: Sudden Cardiac Death in Epilepsy Genetic predisposition to miocarditis? Benefits of using NGS Unexplained sudden cardiac death 10 years old Sudden Death Unexplained sudden cardiac death Disease Genetic Panel Patients Family Long QT Syndrome (LQTS) KCNQ1, KCNH2, SCN5A It is recommended It is recommended Catecholaminergic Polymorphic It is recommended RYR2, CASQ2 It is recommended Ventricular Tachycardia (CPVT) Brugada Syndrome (BrS) SCN5A Can be useful It is recommended Short QT Syndrome (SQTS) KCNH2, KCNQ1, KCNJ2 May be considered It is recommended Hypertrophic Cardiomyopathy MYH7, MYBPC3,TNNT2, TNNI3, It is recommended It is recommended (HCM) TPM1 Arrythmogenic right ventricular DSC2, DSG2, DSP, PKP2, It is recommended Can be useful cardiomyopathy (ARVC) TMEM43, JUP Dilated cardiomyopathy (DCM) LMNA, SCN5A It is recommended It is recommended It is recommended Left Ventricular noncompactation MYH7, ACTC1, TNNT2, Can be useful (LVnC) MYBPC3, LBD3 MYH7, ACTC1, TNNT2, TNNI3, May be considered It is recommended Restrictive cardiomyopathy (RCM) It is recommended Clinically guided It is recommended Sudden Death Survival Forensic Analysis in a Sudden Death RYR2, KCNQ1, KCNH2, It is recommended It is recommended Case SCN5A Unexplained sudden cardiac death 10 years old Sudden Death No mutation in SCN5A, RYR2, KCNQ1, KCNH2 Benefit of using NGS 10 years old Sudden Death Mutation GPD1-L Benefit of using NGS Role of CNVs in Sudden Cardiac Death Exon 6 Exon 7 Exon 8 Exon 9 Benefit of using NGS FBN1 Dup exons 45-65 KCNH2_p.G903R GENETICS: A NEW DIAGNOSTIC TOOL “Doctor, if you had performed a genetic test would my brother still be alive?” If you answer yes (or maybe) to that question, you are in trouble. Thank you .
Load more

Recommended publications
  • Treatment of Aged Mice and Long-Term Durability of AAV-Mediated Gene Therapy in Two Mouse Models of LGMD Eric R
    P.137 Treatment of Aged Mice and Long-term Durability of AAV-Mediated Gene Therapy in Two Mouse Models of LGMD Eric R. Pozsgai, Danielle A. Griffin, Ellyn L. Peterson, Amber Kempton, Oliver Rogers, Young-Eun Seo, Louise R. Rodino-Klapac Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA BACKGROUND RESULTS RESULTS (CONT’D) • The sarcoglycanopathies are a subset of autosomal recessive limb-girdle muscular dystrophies (LGMD) Figure 1. Expression analysis: Immunofluorescence staining and western blot on skeletal • Functional improvement was observed with significantly increased resistance to contraction-induced injury resulting from mutations in the sarcoglycans (α, β, γ, and δ-SG) leading to protein deficiency, loss of in the TA muscle (Figure 3). formation of the sarcoglycan complex, and loss of stabilization of the dystrophin-associated protein muscle indicating biomarker expression in aged, severely diseased muscle complex (DAPC). Figure 3. Functional analysis: Protection of force output following long-term treatment of • Sarcoglycanopathies present as progressive muscular dystrophies starting in the girdle muscles before aged SGCA-/- mice with severely diseased muscle extending to lower and upper extremity muscles, and can also present in the diaphragm and heart, resulting in respiratory and cardiac failure in specific patient subtypes. SKELETAL MUSCLE • Adeno-associated virus (AAV)-mediated gene transfer therapy has shown early signs of potential to treat sarcoglycanopathies. Key considerations include a systematic and stepwise
    [Show full text]
  • Limb-Girdle Muscular Dystrophy
    www.ChildLab.com 800-934-6575 LIMB-GIRDLE MUSCULAR DYSTROPHY What is Limb-Girdle Muscular Dystrophy? Limb-Girdle Muscular Dystrophy (LGMD) is a group of hereditary disorders that cause progressive muscle weakness and wasting of the shoulders and pelvis (hips). There are at least 13 different genes that cause LGMD, each associated with a different subtype. Depending on the subtype of LGMD, the age of onset is variable (childhood, adolescence, or early adulthood) and can affect other muscles of the body. Many persons with LGMD eventually need the assistance of a wheelchair, and currently there is no cure. How is LGMD inherited? LGMD can be inherited by autosomal dominant (AD) or autosomal recessive (AR) modes. The AR subtypes are much more common than the AD types. Of the AR subtypes, LGMD2A (calpain-3) is the most common (30% of cases). LGMD2B (dysferlin) accounts for 20% of cases and the sarcoglycans (LGMD2C-2F) as a group comprise 25%-30% of cases. The various subtypes represent the different protein deficiencies that can cause LGMD. What testing is available for LGMD? Diagnosis of the LGMD subtypes requires biochemical and genetic testing. This information is critical, given that management of the disease is tailored to each individual and each specific subtype. Establishing the specific LGMD subtype is also important for determining inheritance and recurrence risks for the family. The first step in diagnosis for muscular dystrophy is usually a muscle biopsy. Microscopic and protein analysis of the biopsy can often predict the type of muscular dystrophy by analyzing which protein(s) is absent. A muscle biopsy will allow for targeted analysis of the appropriate LGMD gene(s) and can rule out the diagnosis of the more common dystrophinopathies (Duchenne and Becker muscular dystrophies).
    [Show full text]
  • Anti-SGCA Picoband Antibody Catalog # ABO12191
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-SGCA Picoband Antibody Catalog # ABO12191 Specification Anti-SGCA Picoband Antibody - Product Information Application WB Primary Accession Q16586 Host Rabbit Reactivity Human, Mouse, Rat Clonality Polyclonal Format Lyophilized Description Rabbit IgG polyclonal antibody for Alpha-sarcoglycan(SGCA) detection. Tested with WB in Human;Mouse;Rat. Reconstitution Add 0.2ml of distilled water will yield a Anti- SGCA Picoband antibody, ABO12191, concentration of 500ug/ml. Western blottingAll lanes: Anti SGCA (ABO12191) at 0.5ug/mlLane 1: Rat Skeletal Muscle Tissue Lysate at 50ugLane 2: Mouse Anti-SGCA Picoband Antibody - Additional Skeletal Muscle Tissue Lysate at Information 50ugPredicted bind size: 43KDObserved bind size: 43KD Gene ID 6442 Other Names Anti-SGCA Picoband Antibody - Alpha-sarcoglycan, Alpha-SG, 50 kDa Background dystrophin-associated glycoprotein, 50DAG, Adhalin, Dystroglycan-2, SGCA, ADL, DAG2 Alpha-sarcoglycan is a protein that in humans is encoded by the SGCA gene. This gene Calculated MW encodes a component of the 42875 MW KDa dystrophin-glycoprotein complex (DGC), which is critical to the stability of muscle fiber Application Details membranes and to the linking of the actin Western blot, 0.1-0.5 µg/ml, Mouse, Rat, cytoskeleton to the extracellular matrix. Its Human<br> expression is thought to be restricted to striated muscle. Mutations in this gene result in Subcellular Localization type 2D autosomal recessive limb-girdle Cell membrane, sarcolemma ; Single-pass muscular dystrophy. Multiple transcript type I membrane protein . Cytoplasm, variants encoding different isoforms have been cytoskeleton . found for this gene.
    [Show full text]
  • Functional Significance of Gain-Of-Function H19 Lncrna in Skeletal Muscle Differentiation and Anti-Obesity Effects Yajuan Li1†, Yaohua Zhang1†, Qingsong Hu1, Sergey D
    Li et al. Genome Medicine (2021) 13:137 https://doi.org/10.1186/s13073-021-00937-4 RESEARCH Open Access Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects Yajuan Li1†, Yaohua Zhang1†, Qingsong Hu1, Sergey D. Egranov1, Zhen Xing1,2, Zhao Zhang3, Ke Liang1, Youqiong Ye3, Yinghong Pan4,5, Sujash S. Chatterjee4, Brandon Mistretta4, Tina K. Nguyen1, David H. Hawke6, Preethi H. Gunaratne4, Mien-Chie Hung7,8, Leng Han3,9, Liuqing Yang1,10,11* and Chunru Lin1,10* Abstract Background: Exercise training is well established as the most effective way to enhance muscle performance and muscle building. The composition of skeletal muscle fiber type affects systemic energy expenditures, and perturbations in metabolic homeostasis contribute to the onset of obesity and other metabolic dysfunctions. Long noncoding RNAs (lncRNAs) have been demonstrated to play critical roles in diverse cellular processes and diseases, including human cancers; however, the functional importance of lncRNAs in muscle performance, energy balance, and obesity remains elusive. We previously reported that the lncRNA H19 regulates the poly-ubiquitination and protein stability of dystrophin (DMD) in muscular dystrophy. Methods: Here, we identified mouse/human H19-interacting proteins using mouse/human skeletal muscle tissues and liquid chromatography–mass spectrometry (LC-MS). Human induced pluripotent stem-derived skeletal muscle cells (iPSC-SkMC) from a healthy donor and Becker Muscular Dystrophy (BMD) patients were utilized to study DMD post-translational modifications and associated proteins. We identified a gain-of-function (GOF) mutant of H19 and characterized the effects on myoblast differentiation and fusion to myotubes using iPSCs.
    [Show full text]
  • New Tests 2 Test Updates 4 CPT Code Updates 11 Deleted Tests 11 Diagnostics Update Volume XXI, No
    Volume XXI, No. 6 JUNE 2021 MONTHLY TEST UPDATES Diagnostics Update New Tests 2 Test Updates 4 CPT Code Updates 11 Deleted Tests 11 Diagnostics Update Volume XXI, No. 6 | JUNE 2021 New Tests Use Anti-DFS70 antibodies may help identify individuals who do not have an Anti-Carbamylated Protein (CarP) Antibody 520311 ANA-associated Autoimmune Rheumatic Disease (AARD) especially in the absence of significant clinical findings.1 Anti-DFS70 Ab, especially when positive CPT 83516 in isolation (i.e. in the absence of AARD-associated autoantibodies), may Synonyms Anti-CarP antigen antibody; RA marker prevent unnecessary referrals and examinations of ANA-positive individuals.2 Special Instructions This test has not been approved for NY state clients. Limitations This test should be used with clinical findings and other Specimen Serum autoimmune testing; it cannot be used alone to rule out autoimmune disease. Volume 1 mL This test was developed and its performance characteristics determined Minimum Volume 0.5 mL by Labcorp. It has not been cleared or approved by the Food and Drug Container Red-top tube; serum from red-top tube; serum from a gel tube; or Administration. serum gel tube Methodology Enzyme-linked immunosorbent assay (ELISA) Collection Separate serum from cells within one hour of collection. Transfer to a Additional Information Anti-DFS70 antibodies target the dense fine speckled plastic transport tube before shipping. protein of 70 kDa which is identical to Lens Epithelium-Derived Growth Factor Storage Instructions Refrigerate or freeze. or transcription co-activator p75 (LEDGFp75). They are detectable in 2% to 22% Stability of healthy individuals and in less than 1% of patients with AARD are of unknown Temperature Period clinical significance.
    [Show full text]
  • Characterization of the Dysferlin Protein and Its Binding Partners Reveals Rational Design for Therapeutic Strategies for the Treatment of Dysferlinopathies
    Characterization of the dysferlin protein and its binding partners reveals rational design for therapeutic strategies for the treatment of dysferlinopathies Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Sabrina Di Fulvio von Montreal (CAN) Basel, 2013 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Michael Sinnreich Prof. Dr. Martin Spiess Prof. Dr. Markus Rüegg Basel, den 17. SeptemBer 2013 ___________________________________ Prof. Dr. Jörg SchiBler Dekan Acknowledgements I would like to express my gratitude to Professor Michael Sinnreich for giving me the opportunity to work on this exciting project in his lab, for his continuous support and guidance, for sharing his enthusiasm for science and for many stimulating conversations. Many thanks to Professors Martin Spiess and Markus Rüegg for their critical feedback, guidance and helpful discussions. Special thanks go to Dr Bilal Azakir for his guidance and mentorship throughout this thesis, for providing his experience, advice and support. I would also like to express my gratitude towards past and present laB members for creating a stimulating and enjoyaBle work environment, for sharing their support, discussions, technical experiences and for many great laughs: Dr Jon Ashley, Dr Bilal Azakir, Marielle Brockhoff, Dr Perrine Castets, Beat Erne, Ruben Herrendorff, Frances Kern, Dr Jochen Kinter, Dr Maddalena Lino, Dr San Pun and Dr Tatiana Wiktorowitz. A special thank you to Dr Tatiana Wiktorowicz, Dr Perrine Castets, Katherine Starr and Professor Michael Sinnreich for their untiring help during the writing of this thesis. Many thanks to all the professors, researchers, students and employees of the Pharmazentrum and Biozentrum, notaBly those of the seventh floor, and of the DBM for their willingness to impart their knowledge, ideas and technical expertise.
    [Show full text]
  • Chemical Agent and Antibodies B-Raf Inhibitor RAF265
    Supplemental Materials and Methods: Chemical agent and antibodies B-Raf inhibitor RAF265 [5-(2-(5-(trifluromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-trifluoromethyl)phenyl-1-methyl-1H-benzp{D, }imidazol-2- amine] was kindly provided by Novartis Pharma AG and dissolved in solvent ethanol:propylene glycol:2.5% tween-80 (percentage 6:23:71) for oral delivery to mice by gavage. Antibodies to phospho-ERK1/2 Thr202/Tyr204(4370), phosphoMEK1/2(2338 and 9121)), phospho-cyclin D1(3300), cyclin D1 (2978), PLK1 (4513) BIM (2933), BAX (2772), BCL2 (2876) were from Cell Signaling Technology. Additional antibodies for phospho-ERK1,2 detection for western blot were from Promega (V803A), and Santa Cruz (E-Y, SC7383). Total ERK antibody for western blot analysis was K-23 from Santa Cruz (SC-94). Ki67 antibody (ab833) was from ABCAM, Mcl1 antibody (559027) was from BD Biosciences, Factor VIII antibody was from Dako (A082), CD31 antibody was from Dianova, (DIA310), and Cot antibody was from Santa Cruz Biotechnology (sc-373677). For the cyclin D1 second antibody staining was with an Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen, A10042) (1:200 dilution). The pMEK1 fluorescence was developed using the Alexa Fluor 488 chicken anti-rabbit IgG second antibody (1:200 dilution).TUNEL staining kits were from Promega (G2350). Mouse Implant Studies: Biopsy tissues were delivered to research laboratory in ice-cold Dulbecco's Modified Eagle Medium (DMEM) buffer solution. As the tissue mass available from each biopsy was limited, we first passaged the biopsy tissue in Balb/c nu/Foxn1 athymic nude mice (6-8 weeks of age and weighing 22-25g, purchased from Harlan Sprague Dawley, USA) to increase the volume of tumor for further implantation.
    [Show full text]
  • Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy*□S
    crossmark Research Author’s Choice © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy*□S Rolf Turk‡§¶ʈ**, Jordy J. Hsiao¶, Melinda M. Smits¶, Brandon H. Ng¶, Tyler C. Pospisil‡§¶ʈ**, Kayla S. Jones‡§¶ʈ**, Kevin P. Campbell‡§¶ʈ**, and Michael E. Wright¶‡‡ Mutations in genes encoding components of the sar- The muscular dystrophies are hereditary diseases charac- colemmal dystrophin-glycoprotein complex (DGC) are re- terized primarily by the progressive degeneration and weak- sponsible for a large number of muscular dystrophies. As ness of skeletal muscle. Most are caused by deficiencies in such, molecular dissection of the DGC is expected to both proteins associated with the cell membrane (i.e. the sarco- reveal pathological mechanisms, and provides a biologi- lemma in skeletal muscle), and typical features include insta- cal framework for validating new DGC components. Es- bility of the sarcolemma and consequent death of the myofi- tablishment of the molecular composition of plasma- ber (1). membrane protein complexes has been hampered by a One class of muscular dystrophies is caused by mutations lack of suitable biochemical approaches. Here we present in genes that encode components of the sarcolemmal dys- an analytical workflow based upon the principles of pro- tein correlation profiling that has enabled us to model the trophin-glycoprotein complex (DGC). In differentiated skeletal molecular composition of the DGC in mouse skeletal mus- muscle, this structure links the extracellular matrix to the cle. We also report our analysis of protein complexes in intracellular cytoskeleton.
    [Show full text]
  • Genetic Modifiers of Hereditary Neuromuscular Disorders
    cells Article Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy Sholeh Bazrafshan 1, Hani Kushlaf 2 , Mashhood Kakroo 1, John Quinlan 2, Richard C. Becker 1 and Sakthivel Sadayappan 1,* 1 Heart, Lung and Vascular Institute, Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (S.B.); [email protected] (M.K.); [email protected] (R.C.B.) 2 Department of Neurology and Rehabilitation Medicine, Neuromuscular Center, University of Cincinnati Gardner Neuroscience Institute, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (H.K.); [email protected] (J.Q.) * Correspondence: [email protected]; Tel.: +1-513-558-7498 Abstract: Novel genetic variants exist in patients with hereditary neuromuscular disorders (NMD), including muscular dystrophy. These patients also develop cardiac manifestations. However, the association between these gene variants and cardiac abnormalities is understudied. To determine genetic modifiers and features of cardiac disease in NMD patients, we have reviewed electronic medical records of 651 patients referred to the Muscular Dystrophy Association Care Center at the University of Cincinnati and characterized the clinical phenotype of 14 patients correlating with their next-generation sequencing data. The data were retrieved from the electronic medical records of the 14 patients included in the current study and comprised neurologic and cardiac phenotype and genetic reports which included comparative genomic hybridization array and NGS. Novel associations were uncovered in the following eight patients diagnosed with Limb-girdle Muscular Dystrophy, Bethlem Myopathy, Necrotizing Myopathy, Charcot-Marie-Tooth Disease, Peripheral Citation: Bazrafshan, S.; Kushlaf, H.; Kakroo, M.; Quinlan, J.; Becker, R.C.; Polyneuropathy, and Valosin-containing Protein-related Myopathy.
    [Show full text]
  • Human Adipocytes Induce Inflammation And
    Diabetes Volume 64, September 2015 3121 Vanessa Pellegrinelli,1,2 Christine Rouault,1,2,3 Sergio Rodriguez-Cuenca,4 Victorine Albert,1,2,3 Frédérique Edom-Vovard,5,6,7,8 Antonio Vidal-Puig,4 Karine Clément,1,2,3 Gillian S. Butler-Browne,5,6,7,8 and Danièle Lacasa1,2,3 Human Adipocytes Induce Inflammation and Atrophy in Muscle Cells During Obesity Diabetes 2015;64:3121–3134 | DOI: 10.2337/db14-0796 Inflammation and lipid accumulation are hallmarks of phenotype, which could contribute to muscle wasting muscular pathologies resulting from metabolic dis- associated with metabolic disorders. eases such as obesity and type 2 diabetes. During obesity, the hypertrophy of visceral adipose tissue (VAT) contributes to muscle dysfunction, particularly through the dysregulated production of adipokines. We During obesity, hypertrophy of white adipose tissue have investigated the cross talk between human adi- (WAT) is associated with fibro-inflammation and cell pocytes and skeletal muscle cells to identify mecha- dysfunction. However, visceral depot (visceral adipose OBESITY STUDIES nisms linking adiposity and muscular dysfunctions. tissue [VAT]) differs from subcutaneous adipose tissue First, we demonstrated that the secretome of obese (SAT) by its inflammatory status because of its high adipocytes decreased the expression of contractile infiltration with immune cells such as macrophages, T proteins in myotubes, consequently inducing atrophy. lymphocytes, and mast cells (1,2). Hence, VAT hypertro- Using a three-dimensional coculture of human myo- phy is considered an important contributor to obesity- tubes and VAT adipocytes, we showed the decreased related metabolic and cardiovascular diseases (3). In obese expression of genes corresponding to skeletal muscle subjects, hypertrophied adipocytes display abnormal se- contractility complex and myogenesis.
    [Show full text]
  • Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
    International Journal of Molecular Sciences Article Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery Marcello Carotti 1, Martina Scano 1, Irene Fancello 1 , Isabelle Richard 2, Giovanni Risato 1, Mona Bensalah 3, Michela Soardi 1 and Dorianna Sandonà 1,* 1 Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, Italy; [email protected] (M.C.); [email protected] (M.S.); [email protected] (I.F.); [email protected] (G.R.); [email protected] (M.S.) 2 Généthon INSERM, U951, INTEGRARE Research Unit, Univ Evry, Université Paris-Saclay, 91002 Evry, France; [email protected] 3 INSERM, Institut de Myologie, U974, Center for Research in Myology, Sorbonne Université, 75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +39-049-8276028; Fax: +39-049-8276049 Received: 13 February 2020; Accepted: 28 February 2020; Published: 6 March 2020 Abstract: Sarcoglycanopathies are rare limb girdle muscular dystrophies, still incurable, even though symptomatic treatments may slow down the disease progression. Most of the disease-causing defects are missense mutations leading to a folding defective protein, promptly removed by the cell’s quality control, even if possibly functional. Recently, we repurposed small molecules screened for cystic fibrosis as potential therapeutics in sarcoglycanopathy. Indeed, cystic fibrosis transmembrane regulator (CFTR) correctors successfully recovered the defective sarcoglycan-complex in vitro. Our aim was to test the combined administration of some CFTR correctors with C17, the most effective on sarcoglycans identified so far, and evaluate the stability of the rescued sarcoglycan-complex. We treated differentiated myogenic cells from both sarcoglycanopathy and healthy donors, evaluating the global rescue and the sarcolemma localization of the mutated protein, by biotinylation assays and western blot analyses.
    [Show full text]
  • Role in Skeletal Muscle Atrophy ���������������������������������������������������������������������������������������� 267 Anastasia Thoma and Adam P
    Advances in Experimental Medicine and Biology 1088 Junjie Xiao Editor Muscle Atrophy Advances in Experimental Medicine and Biology Volume 1088 Editorial Board IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel ABEL LAJTHA, N.S.Kline Institute for Psychiatric Research, Orangeburg, NY, USA JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA RODOLFO PAOLETTI, University of Milan, Milan, Italy NIMA REZAEI, Tehran University of Medical Sciences, Children’s Medical Center Hospital, Tehran, Iran More information about this series at http://www.springer.com/series/5584 Junjie Xiao Editor Muscle Atrophy Editor Junjie Xiao Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, School of Life Science Shanghai University Shanghai, China ISSN 0065-2598 ISSN 2214-8019 (electronic) Advances in Experimental Medicine and Biology ISBN 978-981-13-1434-6 ISBN 978-981-13-1435-3 (eBook) https://doi.org/10.1007/978-981-13-1435-3 Library of Congress Control Number: 2018958628 © Springer Nature Singapore Pte Ltd. 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]